AIM OF THE STUDY: The extensive neovascularisation of malignant glioma is mainly influenced by vascular endothelial growth factor (VEGF). The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide. METHODS: The effects on glioma growth were investigated in the intracerebral BT4C rat glioma model. ZD6474 30 mg/kg was given alone or in combination with radiotherapy 12 Gy x 1 or with temozolomide 100 mg/kg for 3 days. Two different experiments were performed comparing ZD6474 to radiotherapy or temozolomide. For each experiment 28 animals were randomized into four groups. RESULTS: ZD6474 in combination with radiotherapy significantly decreased tumour area by 66% compared with controls whereas the combination with temozolomide decreased tumour area by 74%. CONCLUSIONS: ZD6474 in combination with two standard modalities in the treatment of malignant glioma, radiotherapy and chemotherapy, markedly decreased the growth of an intracerebral experimental glioma. These results justify further investigations of these therapies in combination.
AIM OF THE STUDY: The extensive neovascularisation of malignant glioma is mainly influenced by vascular endothelial growth factor (VEGF). The effect of ZD6474, a potent inhibitor of VEGF-receptor-2, was evaluated in combination with either radiotherapy or temozolomide. METHODS: The effects on glioma growth were investigated in the intracerebral BT4C rat glioma model. ZD6474 30 mg/kg was given alone or in combination with radiotherapy 12 Gy x 1 or with temozolomide 100 mg/kg for 3 days. Two different experiments were performed comparing ZD6474 to radiotherapy or temozolomide. For each experiment 28 animals were randomized into four groups. RESULTS: ZD6474 in combination with radiotherapy significantly decreased tumour area by 66% compared with controls whereas the combination with temozolomide decreased tumour area by 74%. CONCLUSIONS: ZD6474 in combination with two standard modalities in the treatment of malignant glioma, radiotherapy and chemotherapy, markedly decreased the growth of an intracerebral experimental glioma. These results justify further investigations of these therapies in combination.
Authors: J Nilsson; C Vallbo; D Guo; I Golovleva; B Hallberg; R Henriksson; H Hedman Journal: Biochem Biophys Res Commun Date: 2001-06-29 Impact factor: 3.575
Authors: Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain Journal: Cancer Cell Date: 2004-12 Impact factor: 31.743
Authors: Jeremy N Rich; Sith Sathornsumetee; Stephen T Keir; Mark W Kieran; Andrea Laforme; Arja Kaipainen; Roger E McLendon; Michael W Graner; B K Ahmed Rasheed; Ling Wang; David A Reardon; Anderson J Ryan; Catherine Wheeler; Isaiah Dimery; Darell D Bigner; Henry S Friedman Journal: Clin Cancer Res Date: 2005-11-15 Impact factor: 12.531
Authors: Marya F McCarty; Jane Wey; Oliver Stoeltzing; Wenbiao Liu; Fan Fan; Corazon Bucana; Paul F Mansfield; Anderson J Ryan; Lee M Ellis Journal: Mol Cancer Ther Date: 2004-09 Impact factor: 6.261
Authors: Ricky T Tong; Yves Boucher; Sergey V Kozin; Frank Winkler; Daniel J Hicklin; Rakesh K Jain Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Phyllis R Wachsberger; Richard Yaacov Lawrence; Yi Liu; Xu Xia; Barbara Andersen; Adam P Dicker Journal: J Neurooncol Date: 2011-04-23 Impact factor: 4.130
Authors: Jaya Prabhakaran; Victoria Arango; Vattoly J Majo; Norman R Simpson; Suham A Kassir; Mark D Underwood; Hanish Polavarapu; Jeffrey N Bruce; Peter Canoll; J John Mann; J S Dileep Kumar Journal: Bioorg Med Chem Lett Date: 2012-06-07 Impact factor: 2.823
Authors: Elizabeth R Gerstner; A Gregory Sorensen; Rakesh K Jain; Tracy T Batchelor Journal: Curr Neurol Neurosci Rep Date: 2009-05 Impact factor: 5.081